Short Interest in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expands By 8.1%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 9,500,000 shares, a growth of 8.1% from the December 31st total of 8,790,000 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 5.7 days. Currently, 7.6% of the company’s stock are sold short.

Halozyme Therapeutics Trading Down 0.6 %

Shares of HALO stock opened at $56.28 on Tuesday. The firm has a market cap of $7.16 billion, a P/E ratio of 18.64, a PEG ratio of 0.43 and a beta of 1.25. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm’s 50-day simple moving average is $50.82 and its 200-day simple moving average is $54.33.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HALO shares. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JMP Securities raised their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Finally, Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Louisiana State Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company’s stock worth $1,688,000 after buying an additional 200 shares during the last quarter. Verdence Capital Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 1.9% during the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 252 shares during the period. State of New Jersey Common Pension Fund D raised its stake in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after purchasing an additional 302 shares in the last quarter. Nations Financial Group Inc. IA ADV raised its stake in shares of Halozyme Therapeutics by 2.4% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 328 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.